Organic compounds
AssigneeNovaris AG
InventorsPeter C. Hiestand, Christian Schnell
Life of this patent
Estimating the term…
Abstract
The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Claims6
A method for reducing or preventing or alleviating relapses in Relapsing-Remitting multiple sclerosis in a subject in need thereof, comprising orally administering to said subject a daily dosage of 0.5 mg of a S1P receptor modulator, wherein said S1P receptor modulator is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, or a pharmaceutically acceptable salt thereof.
A method for treating Relapsing-Remitting multiple sclerosis in a subject in need thereof, comprising administering orally to said subject a daily dosage of 0.5 mg of a S1P receptor modulator wherein said S1P receptor modulator is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, or a pharmaceutically acceptable salt thereof.
A method for slowing progression of Relapsing-Remitting multiple sclerosis in a subject in need thereof, comprising orally administering to said subject a daily dosage of 0.5 mg of a S1P receptor modulator, wherein said S1P receptor modulator is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.